MarketAnalysisMarketAnalysis
NASDAQGS:VRTX

Vertex Pharmaceuticals Incorporated - NASDAQGS:VRTX - Comprehensive analysis

Free evaluation through quantitative algorithms Vertex Pharmaceuticals Incorporated - NASDAQGS:VRTX

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

11.66

Market

79

Sector

66

Gross Profit Growth Over Prior Year

10.25

Market

68

Sector

63

EBITDA Growth Over Prior Year

6.65

Market

50

Sector

55

EBITA Growth Over Prior Year

7.05

Market

53

Sector

50

EBIT Growth Over Prior Year

6.62

Market

47

Sector

48

Earnings from Cont. Ops. Growth Over Prior Year

0

Market

0

Sector

0

Net Income Growth Over Prior Year

0

Market

0

Sector

0

Normalized Net Income Growth Over Prior Year

4.54

Market

47

Sector

37

Diluted EPS before Extra Growth Over Prior Year

0

Market

0

Sector

0

A/R Growth Over Prior Year

2.94

Market

54

Sector

62

Inventory Growth Over Prior Year

64

Market

100

Sector

97

PPE Net Growth Over Prior Year

78

Market

100

Sector

94

Total Assets Growth Over Prior Year

-0.87

Market

29

Sector

46

Tangible Book Value Growth Over Prior Year

-7.39

Market

14

Sector

46

Common Equity Growth Over Prior Year

-6.66

Market

15

Sector

46

Cash from Ops. Growth Over Prior Year

0

Market

0

Sector

0

CAPEX Growth Over Prior Year

48.6

Market

94

Sector

85

Dividend per Share Growth Over Prior Year

0

Market

36

Sector

48

Levered Free Cash Flow Growth Over Prior Year

-22.35

Market

17

Sector

23

Unlevered Free Cash Flow Growth Over Prior Year

-22.42

Market

17

Sector

22

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

87

Market

97

Sector

86

SG&A Margin %

12.99

Market

47

Sector

29

EBITDA Margin %

43.3

Market

83

Sector

98

EBITA Margin %

41.9

Market

94

Sector

98

EBIT Margin %

41.7

Market

94

Sector

99

Earnings from Cont. Ops Margin %

-4.86

Market

3

Sector

39

Net Income Margin %

-4.86

Market

4

Sector

39

Net Income Avail. for Common Margin %

-4.86

Market

3

Sector

39

Normalized Net Income Margin %

28.8

Market

98

Sector

99

Levered Free Cash Flow Margin %

24.7

Market

85

Sector

95

Unlevered Free Cash Flow Margin %

24.9

Market

82

Sector

94

Return on Assets %

12.68

Market

90

Sector

97

Return on Capital %

15.71

Market

84

Sector

96

Return on Equity %

-3.15

Market

4

Sector

73

Return on Common Equity %

-3.15

Market

4

Sector

73

Total Asset Turnover

0.49

Market

48

Sector

62

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 41
Momentum: 11
Growth: 51
Profitability: 58

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

7.95

Market

82

Sector

73

TEV/LTM EBITDA

18.59

Market

74

Sector

67

P/LTM Normalized EPS

31.7

Market

55

Sector

55

P/BV

5.83

Market

68

Sector

80

TEV/LTM Unlevered FCF

33.3

Market

64

Sector

71

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

-20.13

Market

4

Sector

17

3M Price Performance

-11.9

Market

11

Sector

30

6M Price Performance

-20.22

Market

11

Sector

47

9M Price Performance

-25.1

Market

12

Sector

50

1Y Price Performance

-19.63

Market

14

Sector

52

Start analyzing Vertex Pharmaceuticals Incorporated - NASDAQGS:VRTX with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports